Initial Medication Dosing for Hypertension and Hyperlipidemia
Hypertension Initial Dosing
For newly diagnosed hypertension, start with lisinopril 10 mg once daily or an equivalent ACE inhibitor/ARB at low dose, titrating to 20-40 mg daily based on blood pressure response. 1
Blood Pressure-Based Treatment Algorithm
BP 130-139/80-89 mmHg: Initiate lifestyle modifications for up to 3 months, then add pharmacologic therapy with ACE inhibitor or ARB if target not achieved 2
BP 140-159/90-99 mmHg: Start single antihypertensive agent immediately alongside lifestyle modifications 2
BP ≥160/100 mmHg: Initiate two antihypertensive medications simultaneously for more effective control 2
Special Populations
Diabetes or pre-diabetes: ACE inhibitor or ARB is preferred first-line due to favorable metabolic profile and renoprotective effects 3
Albuminuria (UACR ≥30 mg/g): ACE inhibitor or ARB is mandatory first-line therapy 2
- Use maximum tolerated dose for UACR ≥300 mg/g 2
Coronary artery disease: ACE inhibitor or ARB recommended as first-line 2
Renal Dosing Adjustments
- CrCl >30 mL/min: No adjustment needed 1
- CrCl 10-30 mL/min: Start lisinopril at 5 mg daily (half usual dose) 1
- CrCl <10 mL/min or hemodialysis: Start lisinopril at 2.5 mg daily 1
Hyperlipidemia Initial Dosing
For elevated LDL cholesterol, initiate pravastatin 20-40 mg once daily or atorvastatin 10 mg once daily as first-line therapy. 2
LDL-Focused Treatment
- Elevated LDL-C or non-HDL-C (triglycerides 200-500 mg/dL):
Triglyceride-Focused Treatment
- Triglycerides ≥500 mg/dL:
Critical Monitoring Requirements
For ACE inhibitors/ARBs: Monitor serum creatinine, eGFR, and potassium at baseline, within 7-14 days after initiation, and at least annually 2, 3
For statins: Monitor for hepatic and skeletal muscle toxicity 2
Important Contraindications
Never combine ACE inhibitor with ARB - increases adverse events (hyperkalemia, syncope, acute kidney injury) without cardiovascular benefit 2, 3
Avoid statin-fibrate combinations except with extreme caution due to myopathy risk; if necessary, use pravastatin with fenofibrate 2
Niacin should be avoided as first-line in patients with lipoatrophy or receiving HIV protease inhibitors 2